Skip to content

Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy for Unexplained Infertility

Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy on Improvement of Endometrial Thickness and Treatment of Unexplained Infertility

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05753098
Enrollment
148
Registered
2023-03-03
Start date
2021-01-15
Completion date
2023-01-31
Last updated
2023-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subfertility, Female

Brief summary

. This study aimed to determine and compare the effect of vaginal sildenafil citrate and estradiol valerate on endometrial thickness, blood flow and pregnancy rates in infertile women.

Detailed description

The study is a randomized controlled trial that was carried on 148 infertile women with unexplained infertility. Patients were divided into 3 groups. Group 1 included 48 patients who received oral estradiol valerate (Cyclo-Progynova 2mg, from day 8th till triggering of ovulation), another 50 patients in group 2 received oral Sildenafil (Respatio 20mg/12hr film coated tablets for 5 days starting from last day of menstruation till ovulation), while group 3 was the control one who included 50 patients were given ovulation induction with CC 50mg/12hr from 2nd to 7th day of cycle. Every patient underwent a transvaginal ultrasound to determine ovulation, number of follicles, and pregnancy rates. Miscarriage, ectopic pregnancy, and multiple pregnancies were tracked for 3 months, as were any adverse consequences.

Interventions

oral estradiol valerate

DRUGSildenafil

PDE5 inhibitor

used for ovulation induction

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* aged between 18 to 40 years * unexplained infertility (primary or secondary) * had a regular menstrual cycle; * patent tubes; * husbands with normal semen parameters.

Exclusion criteria

* hypotension; * cardiovascular, hepatic, and renal diseases; * uncontrolled diabetes mellitus; * anovulatory infertility; * ovarian cysts; * pelvic adhesions; * hyperprolactinemia; * abnormal thyroid functions; * multiple uterine fibroids; * patients on nitrates; * suspicion of endometriosis and adenomyosis, * subjects have known to receive any treatment for fertility in the last six months

Design outcomes

Primary

MeasureTime frameDescription
pregnancy ratesat the end of each of 3 cycles (28 days)measure B HCG and detect number of cases get pregnant in each cycle 28 days

Secondary

MeasureTime frameDescription
ovulation3 monthsmeasuring dominant follicle starting from D9 of the cycle till reaching 18-20mm

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026